OZMOSI Partners with Planview to Advance AI-Driven Pharma Portfolio Management

OZMOSI, a leading provider of structured pharmaceutical development intelligence, announced a strategic partnership with Planview, the leading AI-powered end-to-end platform for Strategic Portfolio Management (SPM) and Digital Product Delivery (DPD).

This integration brings external clinical reality into internal R&D decision-making, so teams can plan based on what's actually happening, not just on what they hope will happen.

The two organizations combine deep expertise in complementary areas, united by a shared focus on improving the quality and usability of data for strategic decision-making. OZMOSI provides structured, machine-readable intelligence across clinical trials, drug development programs, regulatory activity, and scientific literature, built on a consistent taxonomy that standardizes how data is connected and understood. Planview's platform enables organizations to model complex investment scenarios, align initiatives with corporate strategy, and optimize resource allocation.

"AI is only as powerful as the data that fuels it," said Beau Bush, President and Founder of OZMOSI. "Pharmaceutical organizations have no shortage of data, but too often it's fragmented, inconsistent, and difficult to operationalize. By bringing OZMOSI's structured data foundation together with Planview's AI-driven planning capabilities, we're enabling teams to move beyond disconnected analysis and toward truly integrated, forward-looking decision-making."

"Strategic planning in pharmaceutical R&D is becoming increasingly dependent on advanced analytics and AI," said  Louise Allen, Chief Product Officer at Planview. "Integrating OZMOSI's clinical intelligence into Planview's platform enables pharmaceutical leaders to make better decisions by combining trusted external data with AI-driven planning